Two months after passing the Drug Benefit Evaluation Committee, negotiations on drug prices for acute lymphocytic leukemia and lymphoma CAR-T treatments have rarely been concluded.

Leukemia patients are urging the NHIS and Novartis Korea to strengthen Kymriah's access to patients with rapid drug price negotiations. On the 15th, Korea Leukemia Patients Organization pointed out, "Kymriah, which received marketing approval from the MFDS, passed the committee on January 13, but patients are suffering because drug price negotiations have not been concluded." Kymriah's price negotiations will begin on January 27 this year, with the deadline of March 28, considering the 60 days of negotiations.